Forte Biosciences, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 6.75 million compared to USD 2.57 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.17 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5799 USD | -3.35% | -3.51% | -29.43% |
13/05 | Tocagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
18/03 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.43% | 2.18Cr | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.39TCr | |
-1.69% | 2.16TCr | |
-10.60% | 1.9TCr | |
-41.25% | 1.7TCr | |
-15.33% | 1.63TCr | |
+5.80% | 1.41TCr | |
+28.03% | 1.2TCr |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023